NO20065027L - Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet - Google Patents

Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet

Info

Publication number
NO20065027L
NO20065027L NO20065027A NO20065027A NO20065027L NO 20065027 L NO20065027 L NO 20065027L NO 20065027 A NO20065027 A NO 20065027A NO 20065027 A NO20065027 A NO 20065027A NO 20065027 L NO20065027 L NO 20065027L
Authority
NO
Norway
Prior art keywords
cell culture
culture medium
factor viii
polypeptide
biologically active
Prior art date
Application number
NO20065027A
Other languages
English (en)
Other versions
NO325633B1 (no
Inventor
Lars Adamson
Erik Walum
Johan Dixelius
Kristina Lima Lie
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9601855A external-priority patent/SE9601855D0/xx
Publication of NO20065027L publication Critical patent/NO20065027L/no
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO325633B1 publication Critical patent/NO325633B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20065027A 1996-05-14 2006-11-02 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet NO325633B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601855A SE9601855D0 (sv) 1996-05-14 1996-05-14 Process for producing a protein
US1887496P 1996-05-29 1996-05-29
PCT/SE1997/000783 WO1997043436A1 (en) 1996-05-14 1997-05-13 A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Publications (2)

Publication Number Publication Date
NO20065027L true NO20065027L (no) 1999-01-14
NO325633B1 NO325633B1 (no) 2008-06-30

Family

ID=26662616

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19985297A NO325358B1 (no) 1996-05-14 1998-11-13 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant human blodkoaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet.
NO20065027A NO325633B1 (no) 1996-05-14 2006-11-02 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19985297A NO325358B1 (no) 1996-05-14 1998-11-13 Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant human blodkoaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet.

Country Status (13)

Country Link
US (1) US5851800A (no)
EP (1) EP0934424B1 (no)
JP (2) JP2000509994A (no)
AT (2) ATE321141T1 (no)
AU (1) AU716245B2 (no)
CA (1) CA2253287C (no)
DE (2) DE69736391T2 (no)
DK (1) DK0934424T3 (no)
ES (2) ES2270460T3 (no)
NO (2) NO325358B1 (no)
NZ (1) NZ332751A (no)
PT (2) PT934424E (no)
WO (1) WO1997043436A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CZ307715B6 (cs) 1999-02-22 2019-03-06 University Of Connecticut Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ATE330003T1 (de) * 1999-08-05 2006-07-15 Baxter Ag Rekombinanter stabiler zellklon, seine herstellung und verwendung
WO2001052891A1 (fr) * 2000-01-20 2001-07-26 Nippon Organon K. K. Inhibiteurs d'invasion plasmodiale dans des erythrocytes
DK2287288T3 (da) * 2002-07-09 2013-01-07 Baxter Int Medium frit for animalsk protein til dyrkning af celler
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
MXPA05006523A (es) * 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
MXPA05011486A (es) * 2003-04-25 2006-04-18 Immunex Corp Inductores de expresion de proteina recombinante.
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
CN101360820A (zh) 2006-01-04 2009-02-04 巴克斯特国际公司 无寡肽的细胞培养基
LT2126106T (lt) * 2007-02-23 2018-01-10 Sk Chemicals Co., Ltd. Viii faktoriaus ir jo darinių gavimo ir gryninimo būdas
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) * 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
TR201900207T4 (tr) 2008-11-07 2019-02-21 Baxalta GmbH Faktör VIII Formülasyonları
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN103154233A (zh) 2010-10-05 2013-06-12 诺沃—诺迪斯克保健股份有限公司 生产蛋白质的方法
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11179440B2 (en) 2016-11-10 2021-11-23 Yuhan Corporation Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US5279939A (en) * 1986-08-18 1994-01-18 Smithkline Beecham Corporation Protein protease inhibitors from streptomyces
US4891356A (en) * 1987-07-15 1990-01-02 Brigham & Women's Hospital Proteinase inhibitors for treatment of gastrointestinal ulcer disease
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JP2769170B2 (ja) * 1987-12-08 1998-06-25 ザイモジェネティクス，インコーポレイティド 真核細肪中での同時発現
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
WO1990002175A1 (en) * 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
DK457788D0 (da) * 1988-08-16 1988-08-16 Nordisk Gentofte Fremgangsmaade til fremstilling af et oensket polypeptid
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ATE220421T1 (de) * 1990-02-26 2002-07-15 Univ Leland Stanford Junior Identifizierung und expression von insekten- steroidrezeptor-dns-sequenzen
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
US5661034A (en) * 1991-07-18 1997-08-26 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free medium for tissue culture containing tissue inhibitor of metalloproteinases and method for growing cells using the medium
EP0861893A3 (en) * 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
AU7524994A (en) * 1993-08-12 1995-03-14 University Of Maryland Thermostable alkaline metalloprotease produced by a hyphomonas, and preparation thereof
US5631159A (en) * 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives

Also Published As

Publication number Publication date
JP4896999B2 (ja) 2012-03-14
JP2009148271A (ja) 2009-07-09
NO985297D0 (no) 1998-11-13
US5851800A (en) 1998-12-22
CA2253287C (en) 2008-02-19
WO1997043436A1 (en) 1997-11-20
DE69735510T2 (de) 2006-08-24
ES2270460T3 (es) 2007-04-01
NO325633B1 (no) 2008-06-30
DE69736391T2 (de) 2007-08-16
JP2000509994A (ja) 2000-08-08
ATE321141T1 (de) 2006-04-15
DK0934424T3 (da) 2006-11-20
DE69736391D1 (de) 2006-09-07
ES2260524T3 (es) 2006-11-01
AU716245B2 (en) 2000-02-24
CA2253287A1 (en) 1997-11-20
NZ332751A (en) 2000-06-23
EP0934424A1 (en) 1999-08-11
NO985297L (no) 1999-01-14
ATE334223T1 (de) 2006-08-15
EP0934424B1 (en) 2006-07-26
PT934424E (pt) 2006-12-29
DE69735510D1 (de) 2006-05-11
AU2919797A (en) 1997-12-05
PT1318198E (pt) 2006-08-31
NO325358B1 (no) 2008-04-07

Similar Documents

Publication Publication Date Title
NO20065027L (no) Fremgangsmate for fremstilling av en biologisk aktiv, rekombinant, human, koaguleringsfaktor VIII i et celledyrkningsmedium som tillater ekspresjon og sekresjon av polypeptidet
EP2056865B1 (en) Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
RU2006145899A (ru) Ферменты для фармацевтического применения
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US4197291A (en) Hydrolytic enzyme material
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ES2136599T3 (es) Tratamiento de las heridas utilizando peptidos biologicamente activos.
US4329430A (en) Enzyme mixture
US4307081A (en) Enzyme mixture
ES2060942T3 (es) Terapia genetica utilizando celulas estromicas.
DK0832186T3 (da) Erstatningsterapi til dental caries
US4226854A (en) Debridement of devitalized tissue with hydrolytic enzyme product
Limova et al. Treatment of pyoderma gangrenosutn with cultured keratinocyte autografts
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
Glyantsev et al. Crab collagenase in wound debridement
JP3009741B2 (ja) 骨組織の局所的形成のためのプラスミノーゲンアクティベーターの使用
AU2007266775B2 (en) Chymotrypsin from Lucilia sericata larvae and its use for the treatment of wounds
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
JPH06509057A (ja) 促進された創傷治癒
CA1077837A (en) Hydrolytic enzyme material
Blomgren et al. A Clinical Study of Trypure® or Varidase® on Minor Burns
IE890270L (en) Proteins derived from human alpha 2 plasmin inhibitor

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees